Figure 6
Histological changes in spleen, liver, inguinal lymph node and lungs of EBOV-challenge animals and treated with EBOTAb at 1, 2 and 3 days post-challenge. (A) Spleen, untreated (CCB080), day 14 post-challenge. Area of white pulp with severe lymphocyte depletion from a follicle shaped area (asterisk). Arteriole is identified by the arrow. (B) Spleen, EBOTAb-treated on day 3 (CCB130), day 9 post-challenge. Scattered nuclear debris within the red pulp. (C) Liver, untreated (CCB041), day 9 post-challenge. Scattered, single cell, hepatocellular necrosis. (D) Liver, EBOTAb-treated on day 2 (CCB081), day 12 post-challenge. Marked degeneration of a vessel wall with inflammatory cell infiltration. (E) Inguinal lymph node, EBOTAb-treated on day 2 (CCB081), day 12 post-challenge. Higher power image showing prominent lymphocyte apoptosis, with nuclear fragmentation (apoptotic bodies) and scattered macrophages in the superficial cortex. (F) Lung, EBOTAb-treated on day 2 (CCB037), day 14 post-challenge. Perivascular infiltration by mixed inflammatory cells.
